Gnosis Receives CEP Certification for Teicoplanin
PTSM: Pharmaceutical Technology Sourcing and Management
The EDQM grants Gnosis a CEP for teicoplanin, a true fermentation glycopeptide antibiotic produced by actinoplanes teichomyceticus strains.
The European Directorate for the Quality of Medicines (EDQM) has granted Gnosis a certificate of suitability of the European Pharmacopoeia (CEP) for teicoplanin. The CEP certification provides proof that the quality of the substances used in human medicines is suitably controlled by the relevant monographs of the European Pharmacopoeia.
Teicoplanin is a true fermentation glycopeptide antibiotic produced by actinoplanes teichomyceticus strains and is a mixture of glycopeptide components which are currently classified into six main subcomponents known as a specific “Complex”.
The first application for a generic of the reference product was submitted in 2005 through the decentralized procedure (DCP). During the teicoplanin assessment, it was discovered that the compositional profile of glycopeptide subcomponents present in the generic version differed compared to the originator. As the composition of the teicoplanin subcomponents is dependent upon the strain of microorganism and the fermentation conditions used, these may give rise to differences in the composition between the generic and reference product. In order to address the inconsistencies across the EU in terms of the requirements for generics of teicoplanin, a procedure was initiated in 2013 to ensure that the active substance is sufficiently characterized, new tests and limits were proposed, in addition to those currently specified in the monograph.
Gnosis has demonstrated the capability to obtain the same “Complex” profile of the originator, including specific ranges of subcomponents, being the first European company to obtain CEP in compliance with the new tests and limits.
Source: Gnosis
Hesperos, Psilera Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
How Smart Technology is Helping Reach Sustainability Goals in Drug Packaging
June 7th 2025Smart technologies, such as digital and laser printing, incorporated into manufacturing equipment are helping manufacturers align with sustainability goals, according to Sheikh Akbar Ali, general manager and head of Development and Technology for ACG Packaging Materials.
